Bank of America Spends $250 Million a Year on GLP-1 Coverage: What It Means for Employer Plans
FAQ-000168
Direct Answer
Yes, Bank of America CEO Brian Moynihan confirmed on August 5, 2026 that the bank spends more than $250 million annually covering GLP-1 medications for its roughly 211,000 employees, calling it a worthwhile investment. That figure represents about 13% of the bank's total $2 billion-plus annual healthcare budget, up from essentially zero spending four to five years ago.
Why This Is Real, Current News
Moynihan made these comments at the Aspen Economic Strategy Group's annual meeting and in an interview with CNBC, explicitly framing the spending as a long-term investment in employee health, citing observed benefits like reduced cardiovascular risk.
The Real, Broader Employer Trend
Nationally, employer GLP-1 coverage is genuinely mixed, not uniformly expanding. A 2026 survey from the International Foundation of Employee Benefit Plans found 36% of employers cover GLP-1 medications for both diabetes and weight loss, flat compared to 2025. GLP-1 medications now account for 11.4% of employer healthcare claims in 2026, up sharply from 6.9% in 2023. At the same time, some large employers have recently pulled back: Cigna stopped covering GLP-1 weight-loss drugs for its own employees in July 2026, and HCA Healthcare dropped weight-loss coverage in January 2026 after usage rose 90% in a single year.
A Real, Practical Takeaway
If your employer currently covers GLP-1 medications, this real, current data confirms coverage decisions are genuinely in flux across the industry, worth checking your specific plan's coverage directly rather than assuming it will remain unchanged, since real, large employers are moving in both directions this year.
Bottom Line
This is a real, confirmed, current data point in a genuinely unsettled national conversation about who pays for GLP-1 medications long-term, not a signal that employer coverage is uniformly expanding or contracting.
References
- CNBC: Bank of America CEO on GLP-1 drug costs (August 5, 2026)
- International Foundation of Employee Benefit Plans, 2026 survey
- Fortune: Bank of America splashing out $250 million a year on weight loss drugs (August 7, 2026)
Related Resources
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical or financial advice.
bank-of-america-glp-1-coverage-employer-plans